Summary
The NDA provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against National Institute for Health and Care Excellence (NICE) Clinical Guidelines and NICE Quality Standards. The NDA supports improvement in the quality of diabetes care by enabling participating NHS services and organisations to: Assess local practice against NICE guidelines. Compare their care, and care outcomes, with similar services and organisations, identify gaps or shortfalls that are priorities for improvement, identify and share best practice and provide a comprehensive national picture of diabetes care and outcomes in England and Wales.
This data release includes the care process and treatment target measurements for the full 2024-25 audit period (1 April 2024 – 31 March 2025); presented for England primary care, Wales primary care and specialist services (hospital-based care), each with its own separate data file.
Data from primary care in England was collected throughout the audit period. Data for specialist services in England is submitted throughout the year with the April 2024 to March 2025 cut of this data being taken in May 2025. Data from Wales was received in July 2025.
Please note that from 2024-25, the audit period changed from a 15-month period to a 12-month period. For example, the 2023-24 audit period covered January 2023 to March 2024 whereas for 2024-25 the audit period covered April 2024 to March 2025. This means that figures for 2024-25 onwards should not be compared with figures from earlier audit periods. The impact of this audit period change has been published (see related links).
Key Facts
Type 1, England
- There were 284,010 people living with type 1 diabetes in England in 2024-25, an increase from 276,750 in 2023-24.
- People living with diabetes should have all 8 key Care Processes completed every year; this is an important measure of the quality of diabetes care. Nationally, 43% of people with type 1 diabetes had all 8 Care Processes recorded.
- There is a wide variation in the quality of diabetes care received by people living with type 1 diabetes, depending on where they live. The highest ICB 8 Care Process achievement in people with type 1 diabetes is 61.1%; the lowest, 30.3%.
- There are also differences in the completion rates of individual Care Processes: of the 8 Care Processes, those with the highest rate of completion were the recording of smoking status (87%), and measurement of blood pressure (85%), whilst achievement was lower for others, such as the measurement of urinary microalbumin (54.8%) and foot assessments (66.8%).
- Nationally, the percentage of people having no Care Processes recorded was 6%, although this varies between ICBs (excluding detained estates) from 3.1% to 10.4%.
- The achievement of the 3 Treatment Targets* (appropriate control of blood pressure, blood glucose and cholesterol) was 30.7%.
- Of people with type 1 diabetes who had their HbA1c checked, the percentage of people with HbA1c equal to or less than 58mmol/mol* has increased from 39.8% in 2023-24 to 41.5% in 2024-25.
*Note that there are differences in audit period methodology between the data collections of 2023-24 and 2024-25 (from 15 months to 12 months).
Type 2 and Other, England
- There were 3,713,155 people living with type 2 diabetes* in England in 2024-25, an increase from 3,579,075 in 2023-24.
- People living with diabetes should have all 8 key Care Processes completed every year; this is an important measure of the quality of diabetes care. Nationally, 58.2% of people with type 2 diabetes had all 8 Care Processes recorded.
- There is a wide variation in the quality of diabetes care received by people living with type 2 diabetes, depending on where they live. The highest ICB 8 Care Process achievement in people with type 2 diabetes is 73.5%; the lowest, 38.6%.
- There are also differences in the completion rates of individual Care Processes: of the 8 Care Processes, the highest rate of completion were the recording of smoking status (94.3%), and measurement of HbA1c (91.9%), whilst achievement was lower for others, such as the measurement of urinary microalbumin (68.6%) and foot assessments (77.7%).
- The achievement of the 3 Treatment Targets* (appropriate control of blood pressure, blood glucose and cholesterol) was 45.2%, varying between 40.7% and 50.0% between ICBs.
- Structured education is key for people living with diabetes. 87.6% of people with type 2 diabetes were offered structured education within 12 months of diagnosis.
*Note that there are differences in audit period methodology between the data collections of 2023-24 and 2024-25 (from 15 months to 12 months).
Last edited: 13 February 2026 10:41 am
